Iguratimod was initially approved by the United States Food and Drug Administration (FDA) on  April 18, 2012.

Iguratimod is primarily used to treat rheumatoid arthritis, an autoimmune disorder characterized by joint inflammation and pain. As a disease-modifying antirheumatic drug (DMARD), this medication helps reduce inflammation, alleviate symptoms, and potentially slow disease progression. While investigational, it is also being explored for other autoimmune conditions like ankylosing spondylitis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, and Behçet's disease, indicating its potential broader application in managing various inflammatory and immune-related disorders.

Iguratimod is typically administered orally, which means it is taken by mouth. It is available in tablets or capsules that are ingested with water. Always follow your healthcare provider's instructions regarding the correct dosage, timing, and frequency of administration for this medication. 

Iguratimod use may lead to various side effects. Commonly observed effects encompass gastrointestinal discomfort, rash, elevated liver enzymes, and upper respiratory tract infections. In some cases, hematologic changes like anemia or thrombocytopenia may occur. Serious effects involve potential liver and allergic reactions, necessitating prompt medical attention. Vigilance for adverse effects and regular medical monitoring are essential to ensure this medication's safe and effective use.

Be cautious of medication interactions and increased susceptibility to infections while on Iguratimod. Gastrointestinal side effects, such as nausea and diarrhea, may arise. Serious allergic reactions, though rare, can occur.  Elevations in liver enzymes could be observed. Hematologic effects, such as changes in blood cell counts, including anemia or decreased platelet count, are possible. Pregnant and breastfeeding individuals should avoid this medication due to potential risks to the developing fetus or infant.  Mood changes or depression can occur. Individuals may experience respiratory symptoms.

Regularly monitor liver function, including liver enzyme levels, and promptly report any symptoms of liver problems to your healthcare provider. Undergo regular blood tests to monitor blood cell counts and promptly report any signs of unusual bleeding, bruising, or infections. Manage gastrointestinal upset with proper hydration and dietary adjustments, and inform your doctor if symptoms persist. Consider bone health monitoring and supplementation with calcium and vitamin D to mitigate potential effects on bone health. Discuss any history of heart disease, cardiovascular issues, or eye conditions with your doctor, and monitor related symptoms.

Consider serious allergic reactions, particularly if rash, swelling, or breathing difficulties occur. Pregnant and breastfeeding individuals should avoid Iguratimod. Use caution if you have lung, liver, cardiovascular, or eye conditions, and discuss bone health, immunizations, and mental health with your healthcare provider. Limit alcohol consumption, be cautious with driving and machinery if drowsiness occurs, and protect your skin from sunlight. Communicate pre-existing medical conditions, infections, or surgery plans with your doctor. If you experience unusual symptoms, such as respiratory issues or mood changes, seek prompt medical attention. Follow dosing instructions consistently, attend follow-up appointments, and consult your doctor for personalized guidance based on your health profile.

1. Huihui Jiang et al; Molecular mechanisms and clinical application of Iguratimod: A review; Biomedicine & Pharmacotherapy; Published on Feb 2020; Accessed on 09/08/2023; https://pubmed.ncbi.nlm.nih.gov/31918275/
2. Novartis Pharmaceuticals UK Ltd, Electronic medicines compendium (emc), [Revised on 25th Jul 2022] [Accessed on 9th August 2023], https://www.medicines.org.uk/emc/product/6658/smpc#gref
3. Sisi Xie et al; Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape; Frontiers in Pharmacology; Published on 26/02/2020; Accessed on;  09/08/2023 http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7054862/
4. Jie Li et al; Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology; Bone Research; Published on Sept 2019; Accessed on 09/08/2023; http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6804744/

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.